相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi et al.
LANCET (2011)
Atypical fractures of the femur and bisphosphonate therapy A systematic review of case/case series studies
Andrea Giusti et al.
BONE (2010)
The McCune-Albright syndrome: a lethal gene surviving by mosaicism
R. Happle
CLINICAL GENETICS (2010)
Effects of Denosumab on Bone Histomorphometry: The FREEDOM and STAND Studies
Ian R. Reid et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice
Sam D. Molyneux et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison T. Stopeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Skeletal progenitors and the GNAS gene: fibrous dysplasia of bone read through stem cells
Mara Riminucci et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2010)
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study
David Thomas et al.
LANCET ONCOLOGY (2010)
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
Eva Gonzalez-Suarez et al.
NATURE (2010)
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer
Daniel Schramek et al.
NATURE (2010)
Comparison of Effects of the Bisphosphonate Alendronate Versus the RANKL Inhibitor Denosumab on Murine Fracture Healing
Louis C. Gerstenfeld et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas
Shuji Mikami et al.
JOURNAL OF PATHOLOGY (2009)
Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial
Karim Fizazi et al.
JOURNAL OF UROLOGY (2009)
RANK ligand as a therapeutic target for bone metastases and multiple myeloma
G. David Roodman et al.
CANCER TREATMENT REVIEWS (2008)
McCune-Albright syndrome
Claudia E. Dumitrescu et al.
ORPHANET JOURNAL OF RARE DISEASES (2008)
Receptor activator of nuclear Factor-κB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis
Atsushi Sasaki et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Surgery for fibrous dysplasia
Robert P. Stanton
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Fibrous dysplasia as a stem cell disease
Mara Riminucci et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Denosumab in postmenopausal women with low bone mineral density
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone
MT Collins et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Fibrous dysplasia with cartilaginous differentiation (fibrocartilaginous dysplasia): a review, with an illustrative case followed for 18 years
M Kyriakos et al.
SKELETAL RADIOLOGY (2004)
Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone
H Plotkin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia
MS Parisi et al.
BONE (2003)
Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia
MT Collins et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
分享论文
